Axovia Therapeutics is developing the first gene therapy to treat diseases caused by cilia dysfunction.
Vantage Biosciences is an ALSA Ventures company at the forefront of targeting the root cause of vision loss associated with diabetes.
Promatix is an ALSA Group company using multi-omic insights to develop the next generation of cancer therapeutics
Develops novel immuno-oncology therapeutics targeting the intersection between vascular dysfunction and immune suppression to treat solid tumors
World leader in IgE drugs with a pipeline of therapies to treat solid cancer tumours
Pipeline of first in class oncology drugs leveraging a proprietary database